Teleflex Incorporated (TFX) is a publicly traded company in the Healthcare — Medical - Instruments & Supplies industry listed on NYSE. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Teleflex Incorporated is a global medical technology company dedicated to designing, developing, manufacturing, and distributing single-use medical devices. These products are crucial for diagnostic and therapeutic procedures, particularly within critical care and surgical environments worldwide.
Is Teleflex Incorporated stock overvalued or undervalued in 2026?
As of October 5, 2026, Teleflex Incorporated (TFX) trades at $124.12 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Teleflex Incorporated
Market cap $5B · 52 weeks $100 – $142 (12 % below the high) · P/E no earnings · 2027 expected P/E 11.3× · Dividend 1.1 % · Next earnings November 5, 2026 · expected EPS $1.90 · Price as of Oct 5 · accounts published Aug 6.
- Valuation: P/Sales 1.2× (no earnings).
- Business: ROIC 1 % (weak).
- Balance sheet: Net debt/EBITDA 7.7× (fragile).
- Earnings: 7 of 8 (on track).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in pharma: 0 of 4 pass
- R&D / Revenue 7.3 %, fails.
- Gross margin 56.2 %, fails.
- ROIC 1.3 %, fails.
- Net debt / EBITDA 7.7×, fails.
Against its peers (reference peers) — Teleflex Incorporated: P/E —; EV/EBITDA —; ROIC 1.3 %; $5.5B. Stevanato Group S.p.A. (P/E 37.2×; EV/EBITDA 19.3×; ROIC 6.4 %; $5.5B), Merit Medical Systems, Inc. (P/E 40.6×; EV/EBITDA 17.1×; ROIC 5.6 %; $5.1B), Bausch + Lomb Corporation (P/E —; EV/EBITDA 14.7×; ROIC 3.2 %; $6.1B).
Dividend
tight · Yield 1.10 % ($1.35 per share in 2025) · 5-year growth -0 % a year · Free cash flow coverage 6.2× · With $1,000 invested today you'd collect $11.00 a year ($0.92 a month).
Profitability
| Return on Equity | -31.83% |
| Return on Invested Capital | 1.30% |
| Return on Assets | -15.17% |
| Gross Margin | 53.77% |
| Operating Margin | 3.35% |
| Net Margin | -39.58% |
Financial Health
| Debt / Equity | 0.99 |
| Current Ratio | 2.60 |
Price Performance
| 1 month | -9.48% |
| 3 months | -3.92% |
| Year-to-date | +2.62% |
| 1 year | -1.93% |
| 3 years | -36.33% |
| 5 years | -66.51% |
Dividend History
Paid in the last 12 months: $1.3600 per share in 4 payments.
| Date | Amount |
|---|---|
| 2026-08-14 | $0.3400 |
| 2026-05-22 | $0.3400 |
| 2026-03-06 | $0.3400 |
| 2025-11-14 | $0.3400 |
| 2025-08-15 | $0.3400 |
| 2025-05-20 | $0.3400 |
| 2025-03-07 | $0.3400 |
| 2024-11-15 | $0.3400 |
| 2024-08-15 | $0.3400 |
| 2024-05-14 | $0.3400 |
Amounts adjusted for stock splits.
Related companies: ALKS · ARWR · BLCO · CRSP · KRYS · MMSI · PCVX
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of TFX: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks